1. Most Discussed
  2. Gainers & Losers
AHZ 13.5¢

CardioCel® sales growth drives revenue higher

  1. maxmojo

    1,954 Posts.
    5
    Revenues for the group continue to grow with $4.8 million for the half year to December 2014.

    For the three months ending December 2014, the group had total sales of $2.5 million, up 23% from the December 2013 quarter (previous corresponding quarter) and up 10% from the September quarter.

    CardioCel® sales for the first half of the year were around $1 million.

    The company also delivered significant progress with the immunotherapy programs with HVS-2 entering a Phase II study and the HPV heading towards a Phase I/II study

    Admedus is well funded with $9.6 million in cash, and also expects to receive R&D tax rebates this financial year.


    CardioCel® sales expansion

    The number of centres using CardioCel® in both Europe and the US continues to rise.

    Currently, CardioCel® is used in 26 centres in Europe and 23 centres in the US and the Group has continued to expand the market for CardioCel® in the second quarter with Health Canada granting a marketing licence and the company achieving Special Access approval for its use in Singapore.

    Admedus will continue to seek additional approvals in other jurisdictions as part of the global launch of CardioCel®.


    Immunotherapy with Professor Ian Frazer

    In collaboration with Professor Ian Frazer and his team, the company also made significant progress with the immunotherapy vaccine programs.

    During this period, the company announced ethics approval for the HSV-2 Phase II clinical study, which is being initiated, with interim results anticipated towards the end of 2015.

    Admedus also announced the latest HPV pre-clinical data which showed compelling results for the HPV therapeutic vaccine.

    The results showed in the TC-1 model 100% survival and over 87% tumour clearance.

    Having now successfully completed a number of pre-clinical studies with extremely positive results, the team is working to progress the HPV program into clinical studies.


    Analysis

    The number of centres using CardioCel® in both Europe and the US continues to rise and is used in 26 centres in Europe and 23 centres in the U.S. In the second quarter with Health Canada granting a marketing licence and the Company achieving Special Access approval for its use in Singapore the future looks bright for CardioCel®.

    The company is also making significant clinical progress with immunotherapy programs with Professor Ian Frazer’s team, which it will look to commercialise in a pipeline of next generation vaccines.

    Latest HPV pre-clinical data showed compelling results for the HPV therapeutic vaccine with TC-1 model 100% survival and over 87% tumour clearance.

    Having now successfully completed a number of pre-clinical studies with strong results, progression of the HPV programme into clinical studies will be a priority.

    Admedus remains well funded with $9.6 million in cash at the end of December 2014, and also expects to receive R&D tax rebates this financial year.

    http://www.proactiveinvestors.com.a...sales-growth-drives-revenue-higher-60439.html

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top

Thank you for visiting HotCopper

We have detected that you are running ad blocking software.


HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.